labels: industry - general, pharmaceuticals
Strides Arcolab signs partnership with The Clinton Foundation for HIV Drugsnews
13 January 2006

Pharmaceuticals company Strides Arcolab Ltd has tied up with the Clinton Foundation to make available a range of affordable anti-retroviral drugs for the treatment of HIV / AIDS in countries that are under the aegis of the Clinton Foundation HIV / AIDS initiative. The Clinton Foundation makes available low-priced anti-retroviral drugs in various countries.

Speaking at a formal ceremony announcing the agreement at New York, Arun Kumar, group CEO and managing director, Strides Arcolab, assured the company's continuing support to the Clinton Foundation's initiative against HIV / AIDS. "We are committed to supply a comprehensive range of first line and second line anti-retroviral drugs that meet global quality standards at affordable prices."

Speaking on the occasion, former US president Bill Clinton said "Strides Arcolab (India) will offer the ARV efavirenz for $240 per patient per year. This price represents savings of more than 30 per cent from current market rates. Following the agreement, Strides will also supply first-line ARVs under Clinton Foundation agreements.

"Lowering the price of second-line drugs is a major priority for my foundation in 2006. Treatment, once started, is a lifelong commitment, and over time patients move from low-priced first-line drugs to second-line combinations that are at least 10 times more expensive. Keeping the global cost of AIDS treatment sustainable will only be possible if we lower the prices of these medicines."


 search domain-b
  go
 
Strides Arcolab signs partnership with The Clinton Foundation for HIV Drugs